Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.32 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19987482 | 0.89 | KCNH2 (0.47) | KCNH2PDE2ALMNATP53HTT | |
| SCHEMBL19133213 | 0.88 | KCNH2 (0.40) | KCNH2LMNATP53HTTSLC6A4 | |
| SCHEMBL18763947 | 0.87 | NR1I2 (0.38) | KCNH2 | |
| SCHEMBL21725453 | 0.82 | LMNA (0.48) | LMNATP53HTT | |
| SCHEMBL19853061 | 0.82 | MC4R (0.38) | KCNH2PDE2ASLC6A4 | |
| SCHEMBL21725576 | 0.81 | KCNH2 (0.36) | KCNH2LMNATP53HTT | |
| SCHEMBL24217655 | 0.81 | SMN1; SMN2 (0.36) | KCNH2LMNATP53HTT | |
| SCHEMBL19879076 | 0.81 | PDE2A (0.36) | PDE2ALMNAHTT | |
| SCHEMBL19987464 | 0.81 | LMNA (0.39) | KCNH2PDE2ALMNATP53HTT | |
| SCHEMBL23031748 | 0.80 | TP53 (0.38) | KCNH2LMNATP53HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024507-B2 | Compounds as GLP-1R agonists | TERNS PHARMACEUTICALS, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20230159512-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-10399932-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180079712-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12024507-B2 | Compounds as GLP-1R agonists | GLP1R, GIPR, GCGR | KCNH2 2588/4885PDE2A 245/4885LMNA 2472/4885 |
| US-20230159512-A1 | COMPOUNDS AS GLP-1R AGONISTS | GLP1R, GIPR, GCGR | KCNH2 2656/4885PDE2A 251/4885LMNA 2442/4885 |
| US-10399932-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | IDO1, IDO2, INMT | KCNH2 4336/4885PDE2A 858/4885LMNA 4373/4885 |
| US-20180079712-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | IDO1, IDO2, INMT | KCNH2 4336/4885PDE2A 858/4885LMNA 4373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.